INOVIO Receives the US FDA’s Breakthrough Therapy Designation for INO-3107 to Treat Recurrent Respiratory Papillomatosis
Shots:
- The designation was based on the P-I/II trial results evaluating INO-3107 in patients with HPV-6 and/or HPV-11-related RRP. Patients received 4 doses of INO-3107 on Days 0, and 3, 6 & 9wks.
- The findings showed that 81.3% had a decrease in surgical interventions in the year after administration vs the prior year with 28.1% requiring no surgical intervention during or after the treatment. Patients had a median range of 4 surgeries in the year before dosing, median decrease of 3 surgical interventions after dosing
- Immunogenicity results demonstrated that INO-3107 induced cellular responses against HPV 6 & HPV 11 activating CD4+ & CD8+ T cells, these responses were still observed at 52wk. while treatment was found to be well tolerated. The pivotal trial of INO-3107 is expected to be initiated in Q4’24
Ref: PR Newswire | Image: Inovio
Related News:- Inovio Presents Results of INO-5401 + INO-9012 & Libtayo (cemiplimab) for the Treatment of Glioblastoma at ASCO 2022
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
